Rite Aid Corp (RAD)
$7.51 0.00 (0.00%)
19:49 EDT RAD Stock Quote Delayed 15 Minutes
Previous Close $7.51
Market Cap 8.01B
PE Ratio -22.09
Volume (Avg. Vol.)
Day's Range 7.51 - 7.51
52-Week Range 0.43 - 11.37
Dividend & Yield N/A (N/A)
RAD Stock Predictions, Articles, and Rite Aid Corp News
- From InvestorPlace
- From the Web
As with most investments, the future of Rite Aid stock depends on millennials. Here, new Rite Aid CEO Heyward Donigan has both an opportunity as well as significant risks.
Despite its cheap price, Rite Aid stock is hardly what you would call a discount. Instead, it’s a junk equity that you should steer clear from, considering that it doesn’t have an Amazon Counter-like catalyst in the foreseeable future.
RAD stock is coming off of its best seven-day stretch in five years, but this rally may mean nothing in Rite Aid's bigger picture.
RAD stock has been in an awful downtrend... for 15 years. But there's still some value and opportunity here.
Having been gutted in the markets over the years, Rite Aid stock appeals to risk-tolerant contrarians. However, there are other names with similar upside potential but with much more stable fundamentals.
These 8 penny stocks have gone from winners to losers, and while some of them could go back to being winners, not all of them will.
The Amazon deal with Rite Aid has only made RAD stock temporarily interesting. But to sustain momentum, the pharmacy needs a much deeper partnership with the e-commerce giant.
A unique Amazon partnership provides a glimmer of hope for RAD stock, but don't bet on that glimmer of hope until it gets brighter.
Heyward Donigan isn't the reason RAD stock has tanked of late. But, if she doesn't appreciate where Rite Aid is wasting money, she may be the reason Rite Aid stock continues to lose ground.
A package pick-up service sounds promising for Rite Aid, but just like the RAD stock price chart, it’s an uphill battle.
The Amazon catalyst gives RAD stock unique breakout potential from today's depressed levels, but that potential is accompanied by ample risk.
Fundamentally, speculators in Rite Aid stock are ignoring the demographic tailwind that the retail pharmacy’s deal with Amazon provides.
Over the years, CVS stock has incurred some painful losses in the markets. However, bold moves by management make this a compelling contrarian buy.
CVS stock has been bleeding for four years. Now, the light at the end of the tunnel is here for CVS Health.
The stock charts of FITB, MRO and INFO stock are on the verge of major moves. Here's what to look for today.
Walgreens stock tanked after the company reported weak second-quarter results and issued a light outlook, but there's opportunity here.
Canopy Growth, CVS Health, Intercept Pharmaceuticals, Rite Aid and UnitedHealth are our top stock trades to watch for Friday.
From The Street
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!